Myelofibrosis: Symptom Burden, Risk Stratification and Novel Treatments

Monday, August 26, 2024, 8:00 AM - Monday, August 25, 2025, 11:59 PM

AMA PRA Category 1 Credits™ (1.50 hours), AMA PRA Category 1 Credits™ Designated (1.50 hours)


Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by clonal hematopoietic cell expansion with bone marrow fibrosis. The considerable heterogeneity of MF translates into a wide range of outcomes. Given this heterogeneity, risk stratification for individualized management becomes essential in disease treatment. Treatment of MF according to the NCCN treatment guidelines is dependent on several factors—risk stratification, symptom burden, and eligibility for different treatment options; however, the simplified recommendation is to initiate treatment in any patient with MF experiencing symptoms that impact their QoL—specifically, general systemic symptoms or symptomatic splenomegaly.

There are no fees to participate in the activity. Participants must review all activity contents, including the learning objectives, disclosure statements, and post activity assessment to receive CME credit for participation.

Contact Information
Brian Waggoner, Program Manager
CancerNet, LLC
[email protected]

1. Assess pathophysiology, myelofibrosis symptom burden, and risk stratification in identifying myelofibrosis (MF) patients for optimal disease management;
2. Illustrate evidence-based risk-informed NCCN guideline-directed treatment strategies for MF.

PHYSICIAN CREDIT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CancerNet. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSE PRACTIONERS CREDIT
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.5 hours.

PHYSICIAN ASSISTANT/ASSOCIATES CREDIT
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)^TM from organizations accredited by ACCME or a recognized state medical society.

NURSES CREDIT (ANCC)
Amedco, a CME/CE company, and CancerNet jointly sponsor this activity. Amedco is jointly accredited by the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. CancerNet, the medical education company, serves as a content and logistic provider for this activity.

Amedco designates this webinar for a maximum of 1.5 ANCC contact hours for nurses.

COI / Disclosure of Relationships with Ineligible Entities

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

Medical Director & Program Planners
The University of Cincinnati, CancerNet, Amedco, and the peer/content reviewers for this activity have no relevant relationships to report.

CancerNet, LLC
Kamatham A. Naidu, PhD
Brian Waggoner

University of Cincinnati, Center for Continuous Professional Development
Susan P. Tyler, PhD, Associate Dean
Heather Muskopf, Program Director
Elizabeth Shaughnessy, MD Peer Reviewer

Amedco
Justin Kaiser

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Disclaimer Statement
The opinions expressed during this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, CancerNet, and Amedco. The information is presented for the purpose of advancing the attendees’ professional development.

COI / Disclosure of Relationships with Ineligible Entities

In accordance with the ACCME Standards for Integrity and Independence Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24-months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education, or whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

Rami Komrokji, MD
Professor of Oncologic Sciences
Vice Chair-Malignant Hematology Department
H Lee Moffitt Cancer Center & Research Institute
Tampa, FL

Dr. Komrokji discloses that he is on the speaker bureaus for AbbVie, Jazz, PharmaEssentia, Rigel, Servier, Sobi; on the advisory boards for AbbVie, BMS, DSI, Jazz, PharmaEssentia, Rigel, Servier, Sobi, Sumitomo Pharma; is a consultant for Geron, Janssen, Sumitomo Pharma; and received research support from BMS

Raajit Rampal, MD, PhD
Associate Member
Director
MPN and Rare Hematologic Malignancies Program
Director
Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Rampal discloses that he is a consultant for Incyte Corporation, Zentalis, Celgene/BMS, Blueprint, AbbVie, CTI, Stemline, Galecto, Pharmaessentia, Jubilant, Constellation/Morphosys, Sierra Oncology/GSK, Protagonist, Cogent, Sumitomo Dainippon, Kartos, Servier, and Karyopharm; and received research support from Incyte Corporation, Zentalis, Stemline Therapeutics, Constellation Pharmaceuticals, Ryvu

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

This activity is supported by an educational grant from CTI Biopharma Corp., a Sobi company.